Mobic (Meloxicam)

Meloxicam works by selectively blocking the cyclooxygenase‑2 (COX‑2) enzyme, which reduces the production of prostaglandins—chemical mediators that cause inflammation, pain, and fever—thereby providing anti‑inflammatory and analgesic effects.

The appropriate dose of Mobic is determined by the prescribing healthcare professional based on the patient’s condition, age, renal and hepatic function, and other individual factors. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

The safety of meloxicam in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To request Mobic, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mobic (meloxicam) offers a longer half‑life and greater COX‑2 selectivity compared with many non‑selective NSAIDs, which may translate into once‑daily dosing and a potentially lower risk of gastrointestinal irritation, though individual response and safety profiles vary.

Mobic should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original container, protect them from moisture and direct sunlight, and ensure they are out of reach of children.

Mobic is taken orally, usually with a glass of water. It can be taken with or without food, but taking it with food may reduce stomach upset. The exact administration schedule should follow the prescriber’s directions.

Serious risks include gastrointestinal bleeding or ulceration, cardiovascular events such as heart attack or stroke, severe skin reactions like Stevens‑Johnson syndrome, and renal impairment. Patients should be monitored for any signs of these conditions and seek medical attention promptly if they occur.

Mobic should be avoided in patients with known hypersensitivity to meloxicam or other NSAIDs, active gastrointestinal ulceration, severe heart failure, severe renal or hepatic impairment, and in those who have had recent coronary artery bypass graft surgery unless specifically advised by a physician.